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Purpose: Ventilator-associated pneumonia (VAP) is the main infectious complication in cardiac surgery
patients and is associated with an important increase in morbidity and mortality. The aim of our study
was to analyze the impact of VAP on mortality excluding other comorbidities and to study its etiology
and the risk factors for its development.
Materials and Methods: This prospective cohort study included 1610 postoperative cardiac surgery
patients' status post cardiopulmonary bypass (CPB) between July 2004 and January 2008. The primary
outcome measures were the development of VAP and in-hospital mortality.
Results: Ventilator-associated pneumonia was observed in 124 patients (7.7%). Patients with VAP had
a longer length of hospitalization (40.7 ± 35.1 vs 16.1 ± 30.1 days, P b .0001) and greater in-hospital
mortality (49.2% [61/124] vs 2.0% [30/1486], P = .0001) in comparison with patients without VAP.
After performing the Cox multivariant analysis adjustment, VAP was identified as the most important
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19VAP as a risk factor after major cardiac surgery17.30; P = .0001). Other independent risk factors of in-hospital mortality were chronic renal failure
(HR, 2.56), diabetes mellitus (HR, 1.90), CPB time (HR, 1.51), respiratory failure (HR, 2.13), acute
renal failure (HR, 2.39), and mediastinal bleeding of at least 1000 mL (HR, 1.81).
Conclusions: The development of VAP after CPB is the most important independent risk factor for in-
hospital mortality. Identification of effective strategies for the prevention of VAP is needed.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Ventilator-associated pneumonia (VAP) is the most
frequent serious infection among patients undergoing heart
surgery. The prevalence of VAP is estimated to be 7.8% to
21.6% [1-3] and is associated with prolonged hospitalization
[4,5], increased health care costs [6], and a 15% to 45%
attributable mortality [7].
In patients admitted to the intensive care unit (ICU), the
extra mortality due to VAP remains a controversial issue in
the literature. Previous studies have reached conflicting
conclusions regarding the impact of VAP on mortality
[1,8-17]. Although the gross mortality rate is high, there
are doubts as to whether the higher mortality rate is due to
VAP itself or to the seriousness of the underlying illness.
Patients undergoing heart surgery are at a particularly
high risk for the development of VAP due to the presence of
multiple comorbidities, frequent postoperative use of
invasive devices (eg, intraaortic balloon counterpulsation,
pulmonary artery catheter), and the common use of
cardiopulmonary bypass (CPB). At the same time, in-
hospital patients are also at risk for multiple postoperative
events (eg, myocardial infarction [MI], congestive heart
failure, acute renal failure, strokes) [1-4,16,18,19]. These
comorbidities complicate the evaluation of the impact of
VAP on mortality [17]. The repercussions of VAP on in-
hospital mortality have not been adequately studied in the
area of cardiac surgery.
Our working hypothesis was that VAP is the most
important independent risk factor of in-hospital mortality in
cardiac surgery patients. Our main objective was to assess
whether the development of VAP during the postoperative
period after cardiac surgery for patients undergoing CPB is
associated with an excess of in-hospital mortality not
attributable to the underlying severity of the illness or to
the intraoperative and postoperative events. The secondary
aim was to establish risk factors of in-hospital mortality.2. Materials and methods
2.1. Hospital setting and patients
This prospective observational study was carried out in
the “Hospital Clínico Universitario,” a tertiary-level
medical center with 800 beds in Valladolid, Spain. TheDepartment of Cardiac Surgery annually performs approx-
imately 550 open cardiac operations with extracorporeal
circulation in adult patients. Two operating rooms were
routinely used. There was an ICU with 10 beds dedicated
exclusively to the postoperative care of patients who had
undergone cardiac surgery. During a 3.5-year period (July
2004-January 2008), all patients undergoing cardiac
surgery with extracorporeal circulation were potentially
eligible for this investigation; and follow-up continued
until January 2009. No patient was excluded. Patients were
excluded if they were younger than 18 years and if they
had undergone heart transplantation. The hospital's
research commission approved the study. All patients,
preoperatively, provided informed written consent both for
their heart surgery and for their participation in the study.
2.2. Study design, end point, and data collection
A prospective cohort study design was used to segregate
study patients undergoing cardiac surgery with CPB accord-
ing to the presence or absence of VAP. The 2 populations
were compared for in-hospital end point of mortality.
One of the investigators made daily rounds in the ICU to
identify eligible patients and to determine the onset of VAP
based on the diagnostic criteria described below. Because
this was strictly an observational study, the investigators did
not interact with the ICU treating physicians regarding the
diagnosis or management of VAP. Patients were evaluated
for nosocomial pneumonia during mechanical ventilation
and for 48 hours after extubation.
Demographic and clinical characteristics and the data
concerning intraoperative and postoperative course (Table 1)
were prospectively recorded for all patients.
2.3. Techniques and treatment received
The surgical and anesthetic techniques and the treatment
the patient received in the ICU did not differ from ordinary
procedures. After admission to the ICU and verification of
hemodynamic stability, the patients were always placed at a
position of 45°. Gastric protection was routinely carried out
with ranitidine (50 mg intravenously per 12 hours) during the
first 24 hours of admission in the ICU; if it continued to be
required, ranitidine was replaced by sucralfate (1 g orally or
through nasogastric tube every 8 hours). All patients were
extubated in the ICU when hemodynamically stable, with a
Table 1 Characteristics of preoperative, intraoperative, and
postoperative data for patients with and without VAP
Characteristics Patients
with VAP
(n = 124)
Patients
without VAP
(n = 1486)
P
Preoperative values
Age (y) 68.5 ± 10.03 67.8 ± 10.5 .45
Sex, male/female 46 (37.1)/
78 (62.9)
584 (39.3)/
902 (60.7)
.62
Underlying conditions
Chronic renal failure 19 (15.3) 61 (4.1) .0001
Peripheral vascular
disease
6 (6.6) 1 (0.1) .0001
Congestive heart failure 19 (15.3) 4 (0.3) .0001
Hypertension 70 (56.5) 609 (41.0) .001
Diabetes mellitus 36 (29.0) 440 (29.6) .89
Malignant neoplasm 6 (4.8) 0 (0.0) .0001
Chronic obstructive
pulmonary disease
32 (25.8) 336 (22.6) .41
Immunosuppression 12 (9.7) 31 (2.1) .0001
Previous cardiac surgery 8 (6.5) 43 (2.9) .03
Obesity 17 (13.7) 458 (30.8) .0001
Intraoperative values
Surgical procedure,
valve
72 (58.1) 945 (63.6) .22
Surgical procedure,
CABG
34 (27.4) 631 (42.5) .001
Surgical procedure,
valvular + CABG
15 (12.1) 15 (1.0) .0001
Aortic cross-clamp,
(min)
83.1 ± 36.4 67.4 ± 28.0 .0001
Total CPB time (min) 115.9 ± 48.2 94.1 ± 37.2 .0001
Postoperative values
Duration of mechanical
ventilation (d)
25.2 ± 26.2 1.8 ± 7.2 .0001
Cardiac complications 57 (46.0) 39 (2.6) .0001
Respiratory failure 89 (71.8) 79 (5.3) .0001
Acute renal failure 79 (63.7) 25 (1.7) .0001
Stroke 10 (8.1) 9 (0.6) .0001
Reintervention 8 (6.5) 43 (2.9) .03
Mediastinal bleeding
≥1000 mL
15 (12.1) 11 (0.7) .0001
Gastrointestinal
complication
16 (12.9) 3 (0.2) .0001
Values are expressed as number (percentage) or means ± SD. Probability
value of P ≤ .05 was considered to be significant.
20 E. Tamayo et al.Ramsay score of 2 to 3, Tobin index (respiratory rate
[spontaneous]/tidal volume [liters]) less than 105 [20], partial
pressure of arterial oxygen (PaO2) greater than 60 mm Hg,
fraction of inspired oxygen (FIO2) less than 0.4, continuous
positive airway pressure less than 5 mbar, PaCO2 50 mm Hg
and arterial pH greater than 7.35. Ratio PaO2/FIO2 greater
than 200, and there was no significant bleeding.
Mouthwashes with chlorhexidine were carried out twice a
day. Antibiotic therapy for VAP was based on our prior
experience in identifying the most common bacterial patho-gens associated with VAP in our medical ICU as well as
following international guidelines [21]. Antibiotic administra-
tion included initial empirical treatment of methicillin-resistant
Staphylococcus aureus with linezolid or teicoplanin and
treatment of Pseudomonas aeruginosa with at least 1 of the
following antibiotics: imipenem, cefepime, or piperacillin-
tazobactam, in association with amikacin or ciprofloxacin.
2.4. Definitions
2.4.1. Ventilator-associated pneumonia
Ventilator-associated pneumonia was diagnosed upon the
presence of new and/or progressive pulmonary infiltrates on a
chest radiograph plus 2 ormore of the following criteria: fever
(≥38.5°C) or hypothermia (b36°C), leukocytosis (≥12 ×
109/L), purulent tracheobronchial secretions, or a reduction in
PaO2/FIO2 of at least 15% in the previous 48 hours, according
to the definition of the Centers for Disease Control and
Prevention [22]. Patients with a Pugin score greater than 6
were also included as having pneumonia [23]. The isolation
of 1 or more pathogenic microorganisms in significant
bacterial counts was required to confirm the diagnosis of
VAP. We considered as nonpathogenic the isolation (at any
concentration) of the following microorganisms unless
proven otherwise: Viridans group streptococci, coagulase-
negative Staphylococcus, Neisseria species, Corynebacter-
ium species, and Candida species.
Inclusion in the study required collection of both respiratory
and blood samples for microbiological examination. Sampling
of the lower respiratory tract in cases of suspected VAP was
performed by endotracheal aspiration (ETA) and/or telescopic
brush sampling of respiratory secretions. For ETA, we
obtained undiluted tracheal secretions. When aspiration was
unproductive, we irrigated with 5 mL of Ringer lactate
solution. Samples were considered to be positive for VAP
when a bacterial count of at least 104 colony-forming unit per
milliliter for each microorganism was obtained by ETA and at
least 103 colony-forming units per milliliter was obtained by
telescopic brushing. Episodes with more than 1 pathogenic
microorganism isolated in respiratory samples were consid-
ered polymicrobial episodes.
2.5. Appropriate antibiotic therapy
Appropriate empirical antibiotic treatment was defined
when at least 1 of the drugs administered was effective against
the pathogens obtained on the antibiogram and administered
immediately after the microbiological diagnostic test was
carried out. The only exception was the case of P aeruginosa,
in which 2 effective drugs were required.2.6. Mortality
In-hospital mortality was defined as patient deaths
occurring from the moment the patient was admitted to the
21VAP as a risk factor after major cardiac surgeryhospital. Intensive care unit mortality was defined as any
death occurring while a patient was located in an ICU.
2.7. Other postoperative events
2.7.1. Myocardial infarction
Perioperative MI was defined as a new Q wave on
electrocardiogram by the Minnesota code criteria or
myocardium-specific creatine kinase levels of at least
100 ng/mL after surgery [24].
2.7.2. Stroke
Stroke was defined as a focal brain injury that persisted
for more than 24 hours combined with an increase in
disability of at least 1 grade on the Rankin scale [25].
2.7.3. Respiratory failure
This was defined as prolonged ventilator therapy greater
than 72 hours, reintubation, or tracheostomy [26].
2.7.4. Gastrointestinal complication
This was defined as the presence of any episode of
digestive bleeding, cholecystitis, perforation, or necrosis of
the stomach or intestine [26].
2.7.5. Mediastinitis
We used the definition described by the Centers for
Disease Control and Prevention [22].
2.7.6. Acute renal failure
This was defined as a creatinine level higher than 2 mg/dL
(176.8 μmol/L) or a 50% increase in creatinine level
compared with baseline [27].
2.8. Study variables
2.8.1. Outcome variables
The primary outcome variable was in-hospital mortality.
2.8.2. Independent variables
Preoperative, intraoperative, and postoperative potential
risk factors (see below) were defined as independent
variables.2.9. Statistical analysis
All values are expressed as the mean ± SD (continuous
variables) or as a percentage of the group they were
derived from (categorical variables). Data were stored and
analyzed by use of the software SPSS, version 15.0 (SPSS,
Chicago, IL).
Univariate analysis was used to compare the variables for
the outcome groups of interest (patients with VAP vs those
without VAP and nonsurviving patients [in-hospital mortal-
ity] vs survivors). Comparisons were unpaired, and all testsof significance were 2 tailed. Numerical variables were
compared using the Student t test. The χ2 statistic or Fisher
exact test was used to compare categorical variables.
The propensity for in-hospital mortality developing post
coronary artery bypass graft (CABG) was determined
using logistic regression analysis. The potential risk factors
for in-hospital mortality (Table 3), (1) preoperative, (2)
intraoperative, and (3) postoperative, were entered into the
model. Because of the large number (25 variables) of
potential risk factors, we avoided multicollinearity among
the explanatory variables by performing collinearity
diagnostic analyses. We performed the stepwise selection
of variables from the models with the following criteria:
tolerance greater than 0.4 [28] or variance inflation less
than 2.5 [28], condition number less than 10, and variance
of 2 or more variables no greater than 0.5 [29,30]. Using
the same criteria and variables as before, we carried out a
new logistic regression analysis in which only patients
with VAP were included.
Patient survival was described using the product-limit
methodology of Kaplan-Meier. We used Cox proportional
hazards analysis to calculate adjusted hazard ratios (HRs)
and to risk adjust the Kaplan-Meier survival curve for
differences in patient and disease characteristics [31].
Significance was assessed at the P ≤ .05 level.3. Results
3.1. Patient and disease characteristics
During the period of the study, a total of 1610 patients
were included. Mean patient age was 67.8 ± 10.3 years. There
were 60.9% (980/1610) men and 39.1% (630/1610) women.
Ventilator-associated pneumonia after cardiac surgery devel-
oped in 124 (7.7%) of patients, and the mean interval from
surgery to presentation of VAP was 5.7 ± 5.8 days. In 80
(64%) patients, the antibiotic therapy was appropriate.
Patients with VAP (Table 1) had more comorbid
conditions, longer aortic cross-clamp time (P b .0001),
longer total CPB time (P b .0001), longer duration of
mechanical ventilation (P b .0001), and more postoperative
complications including cardiac complications, respiratory
failure, acute renal failure, etc (P b .0001). Patients with
VAP had a longer length of ICU after surgery (29.6 ± 29.4 vs
4.2 ± 8.1 days, P b .001) and length of hospital stay (40.7 ±
35.1 vs 16.1 ± 30.1 days, P b .0001) in comparison with
patients without VAP.
The most commonly isolated pathogens (Table 2)
associated with a nosocomial infection were gram-negative
bacilli (n = 92, 74.2%), in particular, Acinetobacter spp (n =
35, 28.2%) and P aeruginosa (n = 26, 20.9%), followed by
gram-positive bacteria (n = 57, 45.9%), most commonly S
aureus (n = 55, or 44.3%), and yeast (n = 15, 12.1%).
Ventilator-associated pneumonia was polymicrobial in 17
Table 2 Pathogens isolated in patients with VAP
Microorganisms Patients with VAP
(n = 124) n (%)
Gram negative
All 92 (74.2)
Acinetobacter spp 35 (28.2)
Escherichia coli 3 (2.4)
Haemophilus influenzae 15 (12.1)
Klebsiella spp 9 (7.3)
Proteus spp 1 (0.8)
P aeruginosa 26 (20.9)
Serratia spp 2 (1.6)
Stenotrophomonas maltophilia 1 (0.8)
Gram positive
All 57 (45.9)
S aureus
All 55 (44.3)
MSSA 25 (20.1)
MRSA 12 (9.6)
Streptococcus pneumoniae 2 (1.6)
Polymicrobial 17 (13.7)
Values are expressed as number (percentage). MRSA indicates
methicillin-resistant S aureus; MSSA, methicillin-susceptible S aureus.
Table 3 Univariate analysis of potential preoperative,
intraoperative, and postoperative risk factors for in-hospital
mortality after cardiac surgery
Characteristics Nonsurvivors
(n = 91)
Survivors
(n = 1519)
P
Preoperative values
Age (y) 69.9 ± 9.7 67.7 ± 10.6 .06
Sex, male/female 51 (56.0)/
40 (44.0)
929 (61.2)/
590 (38.8)
.33
Underlying conditions
Chronic renal failure 19 (20.9) 61 (4.0) .0001
Peripheral vascular
disease
6 (6.6) 1 (0.1) .0001
Congestive heart
failure
9 (9.9) 14 (0.9) .0001
Hypertension 50 (54.9) 629 (41.4) .01
Diabetes mellitus 35 (38.5) 441 (29.0) .05
Malignant neoplasm 3 (3.3) 3 (0.2) .0001
Chronic obstructive
pulmonary disease
28 (30.8) 340 (22.4) .06
Immunosuppression 7 (7.7) 36 (2.4) .002
Previous cardiac
surgery
4 (4.4) 47 (3.1) .49
Obesity 19 (20.9) 456 (30.0) .06
Intraoperative values
Surgical procedure,
valve
58 (63.7) 959 (63.1) .908
Surgical procedure,
CABG
24 (26.4) 641 (42.2) .003
Surgical procedure,
valvular + CABG
11 (12.1) 19 (1.3) .0001
Aortic cross-clamp
time (min) a
86.7 ± 34.1 67.9 ± 28.3 .0001
Total CPB time (min) 122.4 ± 46.3 94.1 ± 37.5 .0001
Postoperative values
Duration of mechanical
ventilation (h)
599.5 ± 611.1 58.8 ± 217.4 .0001
VAP 61 (67.0) 63 (4.1) .0001
VAP appropriate
antibiotic therapy
35 (38.4) 45 (2.9) .102
Cardiac complications 35 (38.5) 61 (4.0) .0001
Respiratory failure 57 (62.6) 111 (7.3) .0001
Acute renal failure 49 (53.8) 55 (3.6) .0001
Stroke 5 (5.5) 14 (0.9) .0001
Mediastinal bleeding
≥1000 mL
7 (7.7) 19 (1.3) .0001
Gastrointestinal
complication
12 (13.2) 7 (5) .0001
Values are expressed as number (percentages) or means ± SD. P ≤ .05
was considered to be significant.
a Variable that was dropped in the multivariate analysis because of
multicollinearity.
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(44.8%) with VAP.
3.2. Hospital mortality and VAP
The overall rate of in-hospital mortality was 5.6% (91/1610),
and ICU mortality was 4.5% (72/1610). Patients with VAP had
higher in-hospitalmortality (49.2% [61/124] vs 2.0% [30/1486],
P = .0001) and ICU mortality (41.9% [52/124] vs 1.3% [20/
1486], P = .0001) in comparison with patients without VAP.
The attributable in-hospital mortality in appropriately treated
VAP was slightly lower than that in inappropriately treated
VAP, but it was not statistically significant.
Univariate analysis showed that 19 of the 26 variables
were associated with an increased risk of in-hospital mortality
(Table 3). After the collinearity assessment, the aortic cross-
clamp time variable was dropped because of multicollinearity
with the CPB time (Table 3). Eighteen variables were
included in a multivariate analysis after withdrawal of those
variables showing multicollinearity (Table 3).
The crude HR of mortality for patients with VAP was
13.28 (95% confidence interval [CI], 6.14-28.72; P b .0001).
The unadjusted Kaplan-Meier survival curves are shown in
Fig. 1. The adjusted freedom from death for VAP at 30, 60,
and 90 days was 91.1%, 85.2%, and 84.0%, respectively,
compared with 99.0%, 98.6%, and 98.4% for patients
without VAP (P b .0001). After performing the Cox
multivariant analysis adjustment for preoperative, intrao-
perative, and postoperative complications (Table 4), VAP
was identified as the independent in-hospital mortality risk
factor with the highest HR in patients undergoing cardiac
surgery (HR, 8.53; 95% CI, 4.21-17.305; P = .0001). Alsoidentified as independent risk factors of in-hospital mortality
were chronic renal failure (HR, 2.56), diabetes mellitus (HR,
1.90), CPB time (HR, 1.51), respiratory failure (HR, 2.13),
acute renal failure (HR, 2.39), and mediastinal bleeding of at
least 1000 mL (HR, 1.81). The adjusted Kaplan-Meier
survival curves are shown in Fig. 2. The adjusted freedom
Fig. 1 Kaplan-Meier curves showing survival of patients with
ventilator-associated pneumonia (VAP) after cardiopulmonary
bypass (CPB) compared with patients without VAP. Comparison
between groups was performed with the log-rank test.
ig. 2 Adjusted Kaplan-Meier curves (according to the COX
ethod) showing survival of patients with ventilator-associated
neumonia (VAP) after cardiopulmonary bypass compared with
atients without VAP, adjusted for preoperative, intraoperative, and
ostoperative risk factor.
23VAP as a risk factor after major cardiac surgeryfrom death for VAP at 30, 60, and 90 days was 72.6%,
57.1%, and 53.8%, respectively, as compared with 98.9%,
98.5%, and 98.3% for patients without VAP (P b .0001).
In the 124 patients with VAP, the Cox multivariant
analysis adjustment for preoperative, intraoperative, and
postoperative complications identified as independent risk
factors of in-hospital mortality chronic renal failure (HR,
2.70), diabetes mellitus (HR, 2.02), and acute renal failure
(HR, 2.67) (Table 5). Appropriately treated VAP was not
found to be an independent risk factor for in-hospital mortality.4. Discussion
This prospective cohort study was designed to examine
any potential effect of VAP on the in-hospital mortality of
patients undergoing cardiac surgery with CPB and to
differentiate this from the contributing factors concerning
preoperative, intraoperative, and postoperative complica-
tions. In this context, the most relevant findings were that (1)Table 4 Risk factors for in-hospital mortality after cardiac
surgery determined by Cox regression analysis
Characteristics Adjusted
HR
95% CI P
Chronic renal failure 2.56 1.51-4.33 .0001
Diabetes mellitus 1.90 1.22-2.95 .004
CPB time 1.51 1.16-1.97 .002
VAP 8.53 4.21-17.305 .0001
Respiratory failure 2.13 1.17-3.86 .012
Acute renal failure 2.39 1.34-4.27 .003
Mediastinal bleeding
≥ 1000 mL
1.81 1.107-2.97 .018F
m
p
p
pthe development of VAP during postoperative cardiac
surgery is an important factor in determining in-hospital
mortality, increasing the risk of death by 8.53 times, and (2)
other risk factors of in-hospital mortality were chronic renal
failure (HR, 2.56), diabetes mellitus (HR, 1.90), CPB time
(HR, 1.51), respiratory failure (HR, 2.13), acute renal failure
(HR, 2.39), and mediastinal bleeding of at least 1000 mL
(HR, 1.81).
The stratification of risk in cardiac surgery has been
centered on preoperative and intraoperative patient risk
factors (eg, the Tuman, EuroSCORE, or Parsonnet scales of
risk) [32-34]. The EuroSCORE [33], for example, summa-
rizes prognostic factors such as age and sex, comorbidities
(eg, chronic obstructive lung disease and neurologic
impairment), cardiac factors (eg, ejection fraction, recent
MI, and pulmonary artery hypertension), and the type of
surgery [33]. This scoring tool was shown to predict short-
term [35] and long-term [36] mortality.
However, the results of surgery are not only determined
by the patient's preoperative conditions but also depend on
perioperative events such as perioperative myocardial
ischemia, atrial fibrillation, transfusion, stroke, acute renal
failure, time to extubation, etc, which are associated withTable 5 Risk factors for in-hospital mortality in patients with
VAP after cardiac surgery determined by Cox regression
analysis
Characteristics Adjusted HR 95% CI P
Chronic renal failure 2.70 1.50-4.84 .001
Diabetes mellitus 2.02 1.18-3.45 .009
Acute renal failure 2.67 1.40-5.08 .003
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[24-27]. Thus, although most clinical studies analyze the
results of cardiac surgery, they only focus on these
complications, rarely analyzing the repercussions of the
presence of VAP on in-hospital mortality.
Mortality in patients with VAP is a controversial subject
concerning patients admitted to the ICU because the target
population is severely ill and the level of associated mortality
is high. Several studies have attempted to clarify the issue
[3,15,16]. Bueno-Cavanillas et al [15] found that critically ill
patients with a nosocomial infection, mainly bacteremia and
pneumonia, have a higher rate of mortality. Other studies,
using univariate analysis, have suggested that VAP is
associated with an increased risk of fatality; but this
association was not evident in multivariate analyses
[10,11]. The use of stepwise logistic regression to control
for effects of confounding variables has shown that VAP
increases the risk of death [7,12,13], whereas others do not
confirm these conclusions [14]. A recent meta-analysis
showed no evidence of attributable mortality due to VAP in
patients with trauma or acute respiratory distress syndrome.
In other nonspecified patient groups, it was unclear due to
heterogeneity whether mortality was attributable to VAP;
and therefore, the study results could not be quantified [17].
Most of these studies have included patients with diverse
pathologies (medical, surgical, trauma patients, etc), and this
makes drawing conclusions difficult. In addition, the
problem is further complicated by the different criteria and
methods used to diagnose VAP, which in turn makes the
comparison of results even more problematic [37].
Very few studies have been performed on postoperative
cardiac surgery patients. Kollef et al [38], in a study that
included 605 consecutive patients undergoing cardiac
surgery, observed VAP in 9.7% of the patients. Thirty
(5.0%) patients died during hospitalization after cardiac
surgery, and the mortality rate of patients with VAP was
23.7%. Bouza et al [3] analyzed 356 patients and found a
frequency of VAP of 7.8% with an overall mortality of
7.3%. Death was significantly more frequent in patients
with VAP (57.1%) than in any other group. In a study of
1844 patients, Hortal et al [39] found that the cumulative
incidence of VAP during the study period was 5.7%.
Overall in-hospital mortality in the study population was
6.9%, with a mortality rate in patients with VAP of 45.7%
vs 2.8% in patients without VAP (P ≤ .001). However, in
a recent European multicenter study [40], a VAP incidence
rate of 2.2%, lower than that found in our and other studies
[3,38,39], was identified.
These studies included a smaller sample of patients with
VAP than that enrolled here, and they did not take into
account any conflicting factors and did not carry out multiple
regression analyses to evaluate the real impact of VAP on
patient mortality. The rates of VAP (7.7%) and in-hospital
mortality (5.6%) in our study concur with previous findings.
Our study, however, provides a larger patient sample size
(124 patients with VAP). Furthermore, through Cox multipleregression, we determined that patients undergoing cardiac
surgery who develop VAP have a risk of death 8.53 times
higher than those without VAP. This study also shows the
importance of other risk factors of mortality, including
chronic renal failure, diabetes mellitus, CPB time, respiratory
failure, acute renal failure, and mediastinal bleeding of at
least 1000 mL [23-26].
Our study did not find lower mortality in patients with
VAP who had received appropriate antibiotic therapy;
however, inappropriateness in antibiotic treatment has been
associated, in some studies, with worse outcomes in VAP
[41,42], although others have failed to prove this association
[16,21,43].
There are some issues that should be addressed. To begin
with, this study included a single-center regional database. It
is likely that the selection of patients, choice of procedures,
as well as the management of the perioperative period may
be important determinants of VAP; and these parameters
vary widely among cardiac surgical units. Secondly, our
study may be criticized for not evaluating the influence of
variables that could influence the extent to which VAP
increases mortality, such as causative pathogens, the
presence of bacteremia, and the time of acquisition of VAP
[3,4,12,15,16]. This study did not analyze the impact of such
variables on the mortality rate of VAP simply because it was
not the aim of this work. However, the study data referring to
the average time before VAP commences (5.5 days),
appropriate antibiotic therapy (64%), presence of bacteremia
(44.8%), and the distribution of common isolated pathogens
in cultures are in accordance with those found in other
studies [3,16,18,23,38,39].
This study provides data highlighting the clinical history
of VAP in postoperative cardiac surgery patients. It suggests
that the occurrence of VAP is the most important risk factor
associated with in-hospital mortality. However, it cannot be
discarded that other factors or comorbidities before the
development of VAP might have exerted an influence over
its appearance and, subsequently, on the death of the patient.
Other factors identified as independent risk factors were
chronic renal failure, diabetes mellitus, CPB time, respiratory
failure, acute renal failure, and mediastinal bleeding of at
least 1000 mL. Moreover, these data support the need to
develop effective strategies for the prevention of VAP.
Implementation of such interventions should be cost-
effective because it should lower the incidence and lessen
the sequelae of VAP.References
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